专利号:US-6667406-B1 优先权日:1999-03-10 标题 :Methods for the synthesis of complex reduced isoindole, isooxyindole and isooxyquinoline libraries 发明人:SUN SENGEN; MURRAY WILLIAM V 权利人:ORTHO MCNEIL PHARM INC 摘要:Disclosed are methods of synthesizing libraries of diverse complex hexahydroisoindole, hexahydroisooxyindole and octahydroisooxyquinoline compounds through the use of a facile intramolecular Diels Alder reaction. The invention is further directed to methods for synthesizing the libraries on solid supports. The invention is further directed to methods for identifying and isolating such hexahydroisoindole, hexahydroisooxyindole and octahydroisooxyquinoline compounds with useful and diverse activities from such libraries.
专利号:EP-1551403-B1 优先权日:2002-10-10 标 题 :5-substituted 2h-pyrazone-3-carboxylic acid derivatives as antilipolytic agents for the treatment of metabolic-related disorders such as dyslipidemia 发明人:SEMPLE GRAEME; AVERBUJ CLAUDIA; SKINNER PHILIP; GHARBAOUI TAWFIK; SHIN YOUNG-JUN 权利人:ARENA PHARM INC 摘要:The present invention relates to certain pyrazole carboxylic acid derivatives of Formula (Ia), and pharmaceutically acceptable salts thereof, as antilipolytic agents and against for the receptor RUP25, wherein: R2 is H, halogen, C1-12 alkyl or C1-12 haloalkyl; and R3 is C3-6 cycloalkyl, C1-12 alkyl, C1-12 haloalkyl, C3-6 cycloalkyl-C1-4-alkylene, aryl-C1-4-alkylene or heteroaryl-C1-4-alkylene, wherein said aryl-C1-4-alkylene and heteroaryl-C1-4-alkylene can be optionally substituted 1 to 5 substituents selected from the substituents listed in the claims. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for pharmaceutical compositions in combination with other active agents, for example, those agents belonging to the class of alpha-glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers, thiazolidinedione and the like.
专利号:US-2006122240-A1 优先权日:2002-11-05 标题 :Benzotriazoles and methods of prophylaxis or treatment of metabolic-related disorders thereof 发明人:SEMPLE GRAEME; SKINNER PHILIP J; CHERRIER MARTIN C; WEBB PETER; TAMURA SUSAN Y 权利人:ARENA PHARM INC 摘要:The present invention relates to certain benzotriazole carboxylic acid or ester derivatives of Formula (I), pharmaceutically acceptable salts and solvates thereof, which exhibit useful pharmaceutical properties, for example, as agonists for the GPCR referred to as hRUP38. Also provided by the present invention are pharmaceutical compositions containing compounds of the invention, and methods of using the compounds and compositions of the invention in the prophylaxis or treatment of metabolic-related disorders, including dyslipidemia, atherosclerosis, coronary heart disease, insulin resistance, type 2 diabetes, Syndrome-X and the like. In addition, the present invention also provides for the use of the compounds of the invention in combination with other active agents such as those belonging to the class of -glucosidase inhibitors, aldose reductase inhibitors, biguanides, HMG-CoA reductase inhibitors, squalene synthesis inhibitors, fibrates, LDL catabolism enhancers, angiotensin converting enzyme (ACE) inhibitors, insulin secretion enhancers and the like.
1: Son JW, Lee IK, Woo JT, Baik SH, Jang HC, Lee KW, Cha BS, Sung YA, Park TS, Yoo SJ, Yoon KH. A prospective, randomized, multicenter trial comparing the efficacy and safety of the concurrent use of long-acting insulin with mitiglinide or voglibose in patients with type 2 diabetes. Endocr J. 2015;62(12):1049-57. doi: 10.1507/endocrj.EJ15-0325. Epub 2015 Sep 25. doi: 10.1136/bmjdrc-2015-000122. eCollection 2015. 3: Al Azzam KM, Muhammad E. Host-guest Inclusion Complexes between Mitiglinide and the Naturally Occurring Cyclodextrins α, β, and γ: A Theoretical Approach. Adv Pharm Bull. 2015 Jun;5(2):289-91. doi: 10.15171/apb.2015.040. Epub 2015 Jun 1. 4: Tani S, Nagao K, Hirayama A. Differences between Mitiglinide/Voglibose Fixed-dose Combination and Glimepiride in Modifying Low-density Lipoprotein Heterogeneity in Japanese Type-2 Diabetic Patients: A Pilot Study. Drug Res (Stuttg). 2016 Feb;66(2):94-9. doi: 10.1055/s-0035-1549993. Epub 2015 May 26. doi: 10.1517/14656566.2015.1035646. Epub 2015 Apr 16. doi: 10.1620/tjem.235.255. doi: 10.1517/14656566.2014.970531. Epub 2014 Oct 20. doi: 10.1055/s-0034-1387719. Epub 2014 Sep 4. doi: 10.1517/14656566.2014.939070. Epub 2014 Jul 21. doi: 10.1517/14656566.2014.920323. Epub 2014 May 27. Erratum in: Expert Opin Pharmacother. 2014 Aug;15(11):1637. doi: 10.1016/j.bmc.2014.04.059. Epub 2014 May 6. doi: 10.1186/1758-5996-6-48. eCollection 2014.
合成参考文献
参考文献:10.1385/endo:29:2:309 摘要:Mori Y, Ojima K, Fuujimori Y, Fujimori Y, Aoyagi I, Kusama H, Yamazaki Y, Kojima M, Kojima S, Shibata N, Itoh Y, Tajima N. Effects of mitiglinide on glucose-induced insulin release into the portal vein and fat-induced triglyceride elevation in prediabetic and diabetic OLETF rats. Endocrine. 2006 Apr;29(2):309–15. doi: 10.1385/endo:29:2:309. 参考文献:10.1007/s12272-015-0621-8 摘要:Tahara A, Takasu T, Yokono M, Imamura M, Kurosaki E. Effects of the combination of SGLT2 selective inhibitor ipragliflozin and various antidiabetic drugs in type 2 diabetic mice. Archives of Pharmacal Research. 2015 Oct 08;39(2):259–70. doi: 10.1007/s12272-015-0621-8. 参考文献:10.1007/s40261-015-0348-9 摘要:Scott LJ. Teneligliptin: a review in type 2 diabetes. Clin Drug Investig. 2015 Nov;35(11):765–72. doi: 10.1007/s40261-015-0348-9.